Clinical trials: Rectal Cancer, Adenocarcinoma
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Advanced Malignant Tumors
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Trial name
- NCT06764771
- Testing
- BMS-986488, Adagrasib, Cetuximab
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
dMMR/MSI-H-type Rectal Adenocarcinoma
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
Immunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer.
- Trial name
- Neo-IT (NCT07160647)
- Testing
- Ipalolimab and Tovorilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sir Run Run Shaw Hospital
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer, Gastric Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT05788484
- Testing
- CDX-585
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celldex Therapeutics
Breast Carcinoma, Cholangiocarcinoma
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer.
- Conditions
- Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT03563352
- Testing
- Interview, Survey Administration
- Where
- United States
- Sponsor
- University of Southern California
Colon Cancer, Rectal Cancer
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
This phase II, randomized pilot trial studies the effect of the consumption of foods made with resistant starch compared to foods made with corn starch on biomarkers that may be related to colorectal cancer progression in stage…
- Conditions
- Colon Cancer, Rectal Cancer, Cancer Survivor, Colorectal Adenocarcinoma
- Trial name
- NCT03781778
- Testing
- Dietary Intervention (resistant starch), Dietary Intervention (regular starch), Questionnaire Administration
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Cancer
Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining chemotherapy with radiation…
- Trial name
- NCT00002896
- Testing
- chemotherapy, fluorouracil, leucovorin calcium
- Where
- Italy
- Volunteers
- 774 people
- Sponsor
- European Institute of Oncology
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Colorectal Carcinoma, Rectal Prolapse
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic…
- Conditions
- Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
- Trial name
- NCT06926374
- Testing
- Robotic surgery using the Sentire Surgical System
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Colorectal Cancer
Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00967655
- Testing
- panitumumab, capecitabine, irinotecan hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Loma Linda Oncology Medical Group, Inc.
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase I/II trial to study the effectiveness of combining SU5416 and irinotecan in treating patients who have advanced colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00005818
- Testing
- irinotecan hydrochloride, semaxanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have metastatic or locally recurrent colorectal cancer.
- Trial name
- NCT00005085
- Testing
- becatecarin
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
The main objective is to evaluate progression-free survival (PFS) at 4 months. The secondary objectives are to evaluate the objective response rate (OR) (= complete responses (CR) and partial responses (PR)) according to the…
- Trial name
- NCT01442649
- Testing
- Oxaliplatin, Folinic Acid, 5-fluoro-uracil
- Where
- France
- Volunteers
- 133 people
- Sponsor
- UNICANCER
Rectal Adenocarcinoma
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
- Trial name
- DWI_RECT_MRGRT (NCT03961776)
- Testing
- MRI-guided radiotherapy by on-board DWI sequences
- Where
- 2 sites in United States, France
- Volunteers
- 39 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.